Sequent Scientific Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company reported consolidated revenue of ₹4,261.40 million for Q2 FY26, marking a 14.2% year-over-year increase from ₹3,731.60 million in Q2 FY25. However, profit after tax declined by 21.9% to ₹196.00 million compared to ₹251.00 million in the corresponding quarter last year. Compared to the previous quarter ending June 30, 2025, revenue declined slightly by 3.7% from ₹4,414.20 million, while profit increased marginally by 11.5% from ₹175.70 million. The basic earnings per share (EPS) improved substantially to ₹0.59 from ₹0.11 in the year-ago quarter.
| Particulars | Q2 FY26 (₹ million) | Q1 FY26 (₹ million) | Q2 FY25 (₹ million) | Change % QoQ | Change % YoY |
|---|---|---|---|---|---|
| Revenue | 4,261.40 | 4,414.20 | 3,731.60 | -3.5% | +14.2% |
| Profit After Tax | 196.00 | 175.70 | 251.00 | +11.5% | -21.9% |
| Basic EPS (₹) | 0.59 | 0.57 | 0.11 | +3.5% | +436.4% |
Sequent Scientific is one of India’s leading animal health companies, ranked among the top 20 globally with operations in over 90 countries. The company focuses on manufacturing APIs (Active Pharmaceutical Ingredients) and FDFs (Finished Dosage Forms) for the veterinary pharmaceuticals sector. It operates five manufacturing facilities and has a diversified product portfolio that includes over 35 APIs and 1,000+ formulations. Recent strategic developments include approval for a composite scheme of amalgamation with its subsidiary Sequent Research Limited and others, pending National Company Law Tribunal approval. The company is led by Managing Director Rajaram Narayanan and backed by notable investors such as The Carlyle Group, which holds a majority stake.
In the latest quarter, the company faced increased costs including material consumption and employee benefits, which affected profitability despite strong revenue growth. Consolidated total expenses for Q2 FY26 were ₹3,972.80 million, up from ₹3,609.40 million in Q2 FY25. The company reported profit before tax of ₹271.60 million in Q2 FY26, compared to ₹79.00 million same period last year. The company’s strong cash flows and ongoing operational improvements reflect its growth strategy in global veterinary pharmaceuticals. Carlyle Group continues as the prominent investor, supporting Sequent Scientific’s growth trajectory.
This mixed set of results suggests that while Sequent Scientific is successfully expanding its revenue base, it needs to focus on cost control and operational efficiencies to enhance profitability in coming quarters. The company’s ongoing strategic initiatives are expected to strengthen its global presence and financial performance moving forward.
Leave a Reply